1
|
El Ouali EM, Kartibou J, Del Coso J, El Makhzen B, Bouguenouch L, El Harane S, Taib B, Weiss K, Knechtle B, Mesfioui A, Zouhal H. Genotypic and Allelic Distribution of the CD36 rs1761667 Polymorphism in High-Level Moroccan Athletes: A Pilot Study. Genes (Basel) 2024; 15:419. [PMID: 38674354 PMCID: PMC11049038 DOI: 10.3390/genes15040419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2024] [Revised: 03/22/2024] [Accepted: 03/25/2024] [Indexed: 04/28/2024] Open
Abstract
Previous studies have shown that variations in the CD36 gene may affect phenotypes associated with fat metabolism as the CD36 protein facilitates the transport of fatty acids to the mitochondria for oxidation. However, no previous study has tested whether variations in the CD36 gene are associated with sports performance. We investigated the genotypic and allelic distribution of the single-nucleotide polymorphism (SNP) rs1761667 in the CD36 gene in elite Moroccan athletes (cyclists and hockey players) in comparison with healthy non-athletes of the same ethnic origin. Forty-three Moroccan elite male athletes (nineteen cyclists and twenty-four field hockey players) belonging to the national teams of their respective sports (athlete group) were compared to twenty-eight healthy, active, male university students (control group). Genotyping of the CD36 rs1761667 (G>A) SNP was performed via polymerase chain reaction (PCR) and Sanger sequencing. A chi-square (χ2) test was used to assess the Hardy-Weinberg equilibrium (HWE) and to compare allele and genotype frequencies in the "athlete" and "control" groups. The genotypic distribution of the CD36 rs1761667 polymorphism was similar in elite athletes (AA: 23.81, AG: 59.52, and GG: 16.67%) and controls (AA: 19.23, AG: 69.23, and GG: 11.54%; χ2 = 0.67, p = 0.71). However, the genotypic distribution of the CD36 rs1761667 polymorphism was different between cyclists (AA: 0.00, AG: 72.22, and GG: 27.78%) and hockey players (AA: 41.67, AG: 50.00, and GG: 8.33%; χ2 = 10.69, p = 0.004). Specifically, the frequency of the AA genotype was significantly lower in cyclists than in hockey players (p = 0.02). In terms of allele frequency, a significant difference was found between cyclists versus field hockey players (χ2 = 7.72, p = 0.005). Additionally, there was a predominance of the recessive model in cyclists over field hockey players (OR: 0.00, 95% CI: 0.00-0.35, p = 0.002). Our study shows a significant difference between cyclists and field hockey players in terms of the genotypic and allelic frequency of the SNP rs1761667 of the CD36 gene. This divergence suggests a probable association between genetic variations in the CD36 gene and the type of sport in elite Moroccan athletes.
Collapse
Affiliation(s)
- El Mokhtar El Ouali
- Laboratory of Biology and Health, Department of Biology, Ibn Tofail University, Kenitra 14000, Morocco; (E.M.E.O.); (J.K.); (A.M.)
| | - Jihan Kartibou
- Laboratory of Biology and Health, Department of Biology, Ibn Tofail University, Kenitra 14000, Morocco; (E.M.E.O.); (J.K.); (A.M.)
| | - Juan Del Coso
- Sport Sciences Research Centre, Rey Juan Carlos University, 28943 Fuenlabrada, Spain
| | - Badreddine El Makhzen
- Medical Genetics Unit, Central Laboratory, CHU Hassan II, Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohamed Ben Abdellah University, Fez 30040, Morocco; (B.E.M.); (L.B.)
| | - Laila Bouguenouch
- Medical Genetics Unit, Central Laboratory, CHU Hassan II, Faculty of Medicine, Pharmacy and Dentistry, Sidi Mohamed Ben Abdellah University, Fez 30040, Morocco; (B.E.M.); (L.B.)
| | - Sanae El Harane
- Institute of Sports Professions, Ibn Tofail University, Kenitra 14000, Morocco;
| | - Bouchra Taib
- Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland;
| | - Katja Weiss
- Institute of Primary Care, University of Zurich, 8032 Zurich, Switzerland; (K.W.); (B.K.)
| | - Beat Knechtle
- Institute of Primary Care, University of Zurich, 8032 Zurich, Switzerland; (K.W.); (B.K.)
- Medbase St. Gallen Am Vadianplatz, 9000 St. Gallen, Switzerland
| | - Abdelhalem Mesfioui
- Laboratory of Biology and Health, Department of Biology, Ibn Tofail University, Kenitra 14000, Morocco; (E.M.E.O.); (J.K.); (A.M.)
| | - Hassane Zouhal
- M2S (Laboratoire Mouvement, Sport et Santé)—EA 1274, University of Rennes, 35000 Rennes, France
- Institut International des Sciences du Sport (2I2S), 35850 Irodouër, France
| |
Collapse
|
2
|
Hagag RS, Fakhry MM, Ahmed OA, Abdalgeleel SA, Radwan MA, Naguib GG. Assessment of efficacy and safety of two Egyptian protocols for treatment-experienced HCV patients: an observational study. THE EGYPTIAN JOURNAL OF INTERNAL MEDICINE 2022. [DOI: 10.1186/s43162-022-00126-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Abstract
Background
The devastating adverse effects of interferon (IFN) for the treatment of hepatitis C virus (HCV) lead to the emerging of direct acting antiviral agents (DAAs). This investigation was undertaken to assess safety and efficacy of two Egyptian DAA protocols for HCV: sofosbuvir (SOF)/daclatasvir (DCV)/simeprevir (SMV)/ribavirin (RBV) and sofosbuvir (SOF)/ombitasvir (OMB)/paritaprevir (PTV)/ritonavir (RTV)/RBV for 12 weeks in treatment-experienced HCV Egyptian patients.
Methods
It is a retrospective study where 139 patients, out of 400 patients, were divided according to their documented treatment protocol into two groups (Gp1: SOF/DCV/SMV/RBV and Gp2: SOF/PTV/OMB/RTV/RBV). All patients’ physical examination, disease history, laboratory baseline, and end of treatment data were collected from their profiles, evaluated and compared.
Results
Gp1 and Gp2 regimens had achieved sustained virologic response rates (SVR12) of 96.6% and 95.1%, respectively. Hemoglobin, ALT, and AST had decreased significantly (P < 0.05) in the two groups. Total bilirubin level had increased significantly in Gp1 and Gp2 (P = 0.002 and < 0.001, respectively). Creatinine level had increased significantly (P = 0.002) in Gp1 at end of treatment, while Gp2 remained unchanged. Headache and fatigue were the most common side effects in both protocols.
Conclusions
SOF/DCV/SMV/RBV and SOF/PTV/OMB/RTV/RBV regimens achieved high similar efficacy in Egyptian treatment-experienced HCV patients. Even though the outcome was with tolerable side effects, a better treatment regimen was recommended to abate these side effects for the welfare of Egyptian HCV patients.
Collapse
|